← Back

Inner Mongolia Furui Med Sci

Inner Mongolia Furui Medical Science Co., Ltd. produces and sells pharmaceutical drugs in China and internationally. It also develops and sells diagnostic equipment and provides related medical services, including the FibroScan liver fibrosis diagnostic instruments, FibroMeter blood test analysis tools for chronic liver disease, and FibroView data management software. The company offers digital health management services, compound turtle shell softening liver tablets, and prescription drugs. Formerly known as Inner Mongolia FuRui Pharmaceutical Limited Liability Company, it was founded in 1998 and is headquartered in Beijing, China.

Price · split & dividend adjusted
News & notes moving 300049.CS
300049.CS4

Furui Medical Releases 2026 Interim Report with Net Profit of 63.9404 Million Yuan

Furui Medical released its 2026 interim report on August 25, 2026. Total operating revenue was 755 million yuan, net profit attributable to the parent company was 63.9404 million yuan, and net cash inflow from operating activities was 176 million yuan. The latest asset-liability ratio was 28.30 percent, up 0.81 percentage points from the previous quarter. The latest gross margin was 75.76 percent, the latest return on equity was 3.25 percent, and diluted earnings per share was 0.24 yuan. The latest total asset turnover was 0.22 times, down 4.75 percent from the same period last year, and the latest inventory turnover was 1.24 times. The number of shareholders was 24,000, and the top ten shareholders held 83.9079 million shares, accounting for 31.78 percent of total share capital.
Jiemian·25dRead more →